JT001 (sodium)
JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis[1].
Product Specifications
CAS Number
2238820-09-0
Product Name Alternative
NLRP3-IN-19 (sodium)
UNSPSC
12352005
Target
NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jt001-sodium.html
Purity
98.39
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
O=C(NS(=O)(C1=C2OCCCN2N=C1)=O)NC3=C4CCCC4=CC5=C3CCC5.[Na]
Molecular Formula
C19H22N4NaO4S
Molecular Weight
425.46
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
NLRP3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF647 conjugate, 0.1mg/mL
CD106 / VCAM1 (1.4C3), CF405S conjugate, 0.1mg/mL
CD81 / TAPA-1 (1.3.3.22), CF594 conjugate, 0.1mg/mL
CD106 / VCAM1 (1.4C3), CF594 conjugate, 0.1mg/mL
